Immunoglobulin, human normal – Flebogamma® DIF 10%

First-line IVIG for use in CUH is Flebogamma® DIF

Flebogamma® DIF dosing is weight based; ensure accuracy of documented weight before administration

CAUTION: High Administration Risk Rating

Form	Bottles containing Normal Human Immunoglobulin (IVIg) **100mg/mL**: 5g in 50mL, 10g in 100mL, 20g in 200mL
Reconstitution	Already in solution
Compatibility & Stability	N/A
Administration	The solution should be clear or slightly opalescent. Do not use solutions that are cloudy or have deposits. **IV Infusion** Initial rate 0.6mL/kg per hour for 30 minutes. If tolerated, increase to 1.2mL/kg per hour for a further 30 minutes. If the patient tolerates the infusion well, additional increments of 1.2mL/kg/hour may be made at 30 minute intervals up to a maximum of 4.8mL/kg/hour. Use an infusion pump. Infusion rates based on a range of body weights:

Prescribed rate in mL/kg/hr	Patient's weight (kg)						
	40	50	60	70	80	90	100
	Infusion rate in mL/hour						
0.6	24	30	36	42	48	54	60
1.2	48	60	72	84	96	108	120
2.4	96	120	144	168	192	216	240
3.6	144	180	216	252	288	324	360
4.8	192	240	288	336	384	432	480

Documentation Requirements	This is a blood product, therefore batch and expiry should be recorded in patient's notes.
Adverse Drug Reactions	Infusion related reactions: In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.
Monitoring	• Monitor BP, heart rate, oxygen saturation, respiratory rate and temperature during initial rate, hourly during infusion, for one hour after initial infusion and for 20 minutes after subsequent infusions. • Monitor urine output and serum creatinine levels.
Additional Information	• In all patients, IVIg administration requires: - adequate hydration prior to the initiation of the infusion of IVIg - avoidance of concomitant use of loop diuretics. • Patients with rare hereditary problems of fructose intolerance must not take this medicine. Each mL of this medicinal product contains 50 mg of sorbitol. • Prescriber should round dose down to nearest whole vial size to minimise waste.

Information relates to Flebogamma® DIF manufactured by Grifols.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542